VEGFA and cervical carcinoma: Angiogenesis is a validated target in the treatment of advanced cervical cancer.4,5 Preclinical and clinical studies indicated that antiangiogenic therapy improved the efficacy of immune checkpoint inhibitors.16 Apatinib selectively inhibits vascular endothelial growth factor (VEGF) receptor (VEGFR) 2 and showed activity in advanced cervical cancer in retrospective reports.17-19 Camrelizumab is a fully humanized, high-affinity monoclonal antibody against PD-1.